Related Experiment Videos
[Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome]
1Rheumaklinik Oberammergau.
Abstract:
Progressive multifocal leukencephalopathy (PML) is a very rare complication of immunosuppressive or cytostatic treatment of rheumatic diseases. We describe a patient with a mixed connective tissue disease (MCTD) existing for more than 15 years, who had polyarthritis, myositis, scleroderma-like symptoms, pulmonary involvement, and psychosis of undetermined origin. After a 12-year low-dose corticosteroid therapy and a 4-year azathioprin therapy a quickly progressive PML developed; symptoms included: difficulty in urinating, bladder, articulation, spastic hemiplegia, eye movement malfunction. The patient died after after a few months. PML is an important consideration in the differential diagnosis when a patient with MCTD develops neurologic symptoms.
Insights
Progressive multifocal leukencephalopathy (PML) is a rare complication in rheumatic disease patients undergoing immunosuppressive therapy. This case highlights PML as a critical differential diagnosis for neurological symptoms in mixed connective tissue disease (MCTD).
Area of Science:
- Neuroimmunology
- Rheumatology
- Infectious Diseases
Background:
- Mixed connective tissue disease (MCTD) is a chronic autoimmune disorder.
- Immunosuppressive therapies, including corticosteroids and azathioprine, are used to manage rheumatic diseases.
- Progressive multifocal leukencephalopathy (PML) is a rare opportunistic infection of the brain.
Observation:
- A patient with a 15-year history of MCTD developed severe neurological symptoms.
- The patient had undergone prolonged low-dose corticosteroid and azathioprine treatment.
- Neurological manifestations included urinary, speech, motor, and visual impairments.
Findings:
- The patient rapidly progressed to a fatal outcome within months.
- The clinical presentation and patient history were consistent with progressive multifocal leukencephalopathy (PML).
- PML was confirmed as a complication of long-term immunosuppressive therapy in an MCTD patient.
Implications:
- PML should be considered in the differential diagnosis of neurological deterioration in MCTD patients.
- Awareness of PML risk is crucial for clinicians managing rheumatic diseases with immunosuppressants.
- This case underscores the importance of early recognition and diagnosis of PML in immunocompromised individuals.